Phase III & cash constrained

Phase III & cash constrained

Company 3Q08 oper loss 9/30/08 cash Years cash Lead program
Active Biotech (SSE:ACTI) (A) $9.0 $28.1 0.78 Anyara in Ph III for renal cancer; laquinimod, which is partnered with Teva (NASDAQ:TEVA), in

Read the full 469 word article

How to gain access

Continue reading with a
two-week free trial.